Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
View Patent ↗The present invention is based on the discovery of genetic polymorphisms that are associated with myocardial infarction. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
1. A method of determining whether a human has an increased risk for myocardial infarction (MI), comprising testing nucleic acid from said human for the presence or absence of G at a polymorphism in gene LPA as represented by position 101 of SEQ ID NO:28,344 or C at position 101 of its complement, wherein the presence of said G or said C indicates said human has an increased risk for MI as compared to a human who is homozygous for A at position 101 of SEQ ID NO:28,344 or homozygous for T at position 101 of its complement.
2. The method of claim 1 , wherein said nucleic acid is a nucleic acid extract from a biological sample from said human.
3. The method of claim 2 , wherein said biological sample is blood, saliva, or buccal cells.
4. The method of claim 2 , further comprising preparing said nucleic acid extract from said biological sample prior to said testing step.
5. The method of claim 4 , further comprising obtaining said biological sample from said human prior to said preparing step.
6. The method of claim 1 , wherein said testing step comprises nucleic acid amplification.
7. The method of claim 6 , wherein said nucleic acid amplification is carried out by polymerase chain reaction.
8. The method of claim 1 , further comprising correlating the presence of said G or said C with an increased risk for MI.
9. The method of claim 8 , wherein said correlating step is performed by computer software.
10. The method of claim 1 , further comprising correlating the absence of said G or said C with no increased risk for MI.
11. The method of claim 10 , wherein said correlating step is performed by computer software.
12. The method of claim 1 , wherein said testing is performed using sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, single-stranded conformation polymorphism analysis, or denaturing gradient gel electrophoresis (DGGE).
13. The method of claim 1 , wherein said testing is performed using an allele-specific method.
14. The method of claim 13 , wherein said allele-specific method is allele-specific probe hybridization, allele-specific primer extension, or allele-specific amplification.
15. The method of claim 13 , wherein said testing is carried out using an allele-specific primer comprising SEQ ID NO:73620 or SEQ ID NO:73621.
16. The method of claim 13 , wherein said allele-specific method detects said G or said C.
17. The method of claim 1 which is an automated method.
18. A method of determining whether a human has a decreased risk for myocardial infarction (MI), comprising testing nucleic acid from said human for the presence or absence of A at a polymorphism in gene LPA as represented by position 101 of SEQ ID NO:28,344 or T at position 101 of its complement, wherein said human who is homozygous for said A or said T has a decreased risk for MI as compared to a human who has G at position 101 of SEQ ID NO:28,344 or C at position 101 of its complement.
19. The method of claim 18 , further comprising correlating the presence of said A or said T with a decreased risk for MI.
20. The method of claim 19 , wherein said correlating step is performed by computer software.
21. The method of claim 18 , wherein said nucleic acid is a nucleic acid extract from a biological sample from said human.
22. The method of claim 21 , wherein said biological sample is blood, saliva, or buccal cells.
23. The method of claim 21 , further comprising preparing said nucleic acid extract from said biological sample prior to said testing step.
24. The method of claim 23 , further comprising obtaining said biological sample from said human prior to said preparing step.
25. The method of claim 18 , wherein said testing step comprises nucleic acid amplification.
26. The method of claim 25 , wherein said nucleic acid amplification is carried out by polymerase chain reaction.
27. The method of claim 18 , wherein said testing is performed using sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, single-stranded conformation polymorphism analysis, or denaturing gradient gel electrophoresis (DGGE).
28. The method of claim 18 , wherein said testing is performed using an allele-specific method.
29. The method of claim 28 , wherein said allele-specific method is allele-specific probe hybridization, allele-specific primer extension, or allele-specific amplification.
30. The method of claim 28 , wherein said testing is carried out using an allele-specific primer comprising SEQ ID NO:73620 or SEQ ID NO:73621.
31. The method of claim 28 , wherein said allele-specific method detects said A or said T.
32. The method of claim 18 which is an automated method.
33. A method of determining whether a human has an increased risk for myocardial infarction (MI), comprising:
a) testing nucleic acid from said human for the presence or absence of G at a polymorphism in gene LPA as represented by position 101 of SEQ ID NO:28,344 or C at position 101 of its complement; and
b) correlating the presence of said G or said C with said human having said increased risk for MI, or the absence of said G or said C with said human having no said increased risk for MI.
34. The method of claim 33 , wherein said correlating step is performed by computer software.
35. The method of claim 33 , wherein said nucleic acid is a nucleic acid extract from a biological sample from said human.
36. The method of claim 34 , wherein said biological sample is blood, saliva, or buccal cells.
37. The method of claim 35 , further comprising preparing said nucleic acid extract from said biological sample prior to said testing step.
38. The method of claim 37 , further comprising obtaining said biological sample from said human prior to said preparing step.
39. The method of claim 33 , wherein said testing step comprises nucleic acid amplification.
40. The method of claim 39 , wherein said nucleic acid amplification is carried out by polymerase chain reaction.
41. The method of claim 33 , wherein said testing is performed using sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, single-stranded conformation polymorphism analysis, or denaturing gradient gel electrophoresis (DGGE).
42. The method of claim 33 , wherein said testing is performed using an allele-specific method.
43. The method of claim 42 , wherein said allele-specific method is allele-specific probe hybridization, allele-specific primer extension, or allele-specific amplification.
44. The method of claim 42 , wherein said testing is carried out using an allele-specific primer comprising SEQ ID NO:73620 or SEQ ID NO:73621.
45. The method of claim 42 , wherein said allele-specific method detects said G or said C.
46. The method of claim 33 which is an automated method.
47. The method of claim 1 , wherein said human is homozygous for said G or said C.
48. The method of claim 33 , wherein said human is homozygous for said G or said C.
49. The method of claim 1 , wherein said human is heterozygous for said G or said C.
50. The method of claim 33 , wherein said human is heterozygous for said G or said C.